Search IBA Dosimetry

Back to overview

SBRT part 1: Impact of PSMA PET on the management of patients with oligo metastatic prostate cancer

Jeremie Calais MD MScDirector of the Clinical Research Program of the Nuclear Medicine and
Theranostics Division, UCLA

3 min. (open access preview)20 min. (full presentation, logged-in members)

Learn about the concept of oligometastatic disease on prostate cancer patients and the importance of highly sensitive and specific PET PSMA imaging in the therapy management of those patients.

Back to overview